Barclays raised the firm's price target on Centene to $75 from $63 and keeps an Overweight rating on the shares. The firm believes the managed care stock moves post the Q1 reports are "durable." It continues to prefer managed care over facilities, saying inflation and commercial mix represent increasing drivers of provider earnings risk. Barclays adjusted ratings and targets in the group.
